mifamurtide

mifamurtide

A fully synthetic lipophilic derivative of muramyl dipeptide, which is an immune stimulatory component of cell walls from Mycobacterium, used to manage high-grade, non-metastasising, resectable osteosarcoma after surgical excision in children to young adults (age 2 to 30).
 
Adverse effects
Fever (90%), tachycardia (50%), constipation (10%), vomiting, fatigue, infections, anaemia, anorexia, headache, diarrhoea.
Prognosis
Mifamurtide-treated patients have a 30% lower mortality than those treated with chemotherapy.